Cookies help us improve your experience. We use cookies to improve website functionality and performance throughout upharma-c.com. Click "accept all cookies” to continue browsing the site with its full range of features enabled.

Short Bowel Syndrome—Pre-Market Entry Study

Task:
To assess the opportunity of accessing the local market.
Task:
To assess the opportunity of accessing the local market.
Client:
EU-based Market Access consultancy.
Region:
Ukraine
Deliverables:
  • Detailed report on the Short Bowel Syndrome in Ukraine.
  • Regulatory environment overview.
  • Pricing & Reimbursement status.
  • Map of key stakeholders and decision-makers.
Product in focus:

Teduglutide brand—the first and only long-term therapy indicated for the treatment of patients with SBS-IF (orphan disease).

Key areas covered in the project:
  • Analysis of the short bowel syndrome-intestinal failure (SBS-IF) market in the country.
  • Assessment of the existing competitive environment in the core market.
  • Identification of the total patients' population for the targeted indication.
  • Estimation of time to achieve public funding.
  • Overview of the public funding of medicines in Ukraine.
  • Overview of the situation concerning the public funding of orphan drugs in the country.
  • Mapping decision-makers in the area of demand forming for orphan drugs in Ukraine.‍


Project
leads

Eugene BROVKO
Partner, Pharma & MedTech Market Access

Download
our E-Brochure